Cemiplimab for early stage non-small cell lung cancer before surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests giving Cemiplimab, an immunotherapy drug that helps your immune system fight cancer, before surgery to remove early stage non-small cell lung cancer. It aims to see if this approach can improve outcomes for people with small tumors that are more aggressive based on PET scan activity or cell appearance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has not spread to lymph nodes and is between 2 and 3.9 cm in size.
- Your tumor shows high activity on a PET scan (SUVmax over 6.2) or the cells look moderate to poorly differentiated under a microscope.
- You can safely undergo lung surgery, with your lung function tests showing predicted remaining breathing capacity of at least 40%.
- You are in good daily health (able to do normal activities) and have adequate organ function.
- You do not have known ALK or EGFR mutations in your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
This trial tests if the immunotherapy drug cemiplimab, given before and after surgery, can help treat early-stage non-small cell lung cancer that has high levels of a protein called PD-L1. If you have stage II or IIIA lung cancer that can be surgically removed and your tumor has PD-L1 expression of 50% or more, you may be eligible.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.